278 related articles for article (PubMed ID: 28011222)
1. Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.
Healy JR; Bezawada P; Griggs NW; Devereaux AL; Matsumoto RR; Traynor JR; Coop A; Cunningham CW
Bioorg Med Chem Lett; 2017 Feb; 27(3):666-669. PubMed ID: 28011222
[TBL] [Abstract][Full Text] [Related]
2. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
[TBL] [Abstract][Full Text] [Related]
3. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
[TBL] [Abstract][Full Text] [Related]
4. Peripheral antinociceptive effects of a bifunctional μ and δ opioid receptor ligand in rat model of inflammatory bladder pain.
Terashvili M; Talluri B; Palangmonthip W; Iczkowski KA; Sanvanson P; Medda BK; Banerjee B; Cunningham CW; Sengupta JN
Neuropharmacology; 2021 Sep; 196():108701. PubMed ID: 34256047
[TBL] [Abstract][Full Text] [Related]
5. Development of novel LP1-based analogues with enhanced delta opioid receptor profile.
Pasquinucci L; Turnaturi R; Prezzavento O; Arena E; Aricò G; Georgoussi Z; Parenti R; Cantarella G; Parenti C
Bioorg Med Chem; 2017 Sep; 25(17):4745-4752. PubMed ID: 28734666
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, Biological, and Structural Explorations of New Zwitterionic Derivatives of 14- O-Methyloxymorphone, as Potent μ/δ Opioid Agonists and Peripherally Selective Antinociceptives.
Spetea M; Rief SB; Haddou TB; Fink M; Kristeva E; Mittendorfer H; Haas S; Hummer N; Follia V; Guerrieri E; Asim MF; Sturm S; Schmidhammer H
J Med Chem; 2019 Jan; 62(2):641-653. PubMed ID: 30571123
[TBL] [Abstract][Full Text] [Related]
7. Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
Mosberg HI; Yeomans L; Harland AA; Bender AM; Sobczyk-Kojiro K; Anand JP; Clark MJ; Jutkiewicz EM; Traynor JR
J Med Chem; 2013 Mar; 56(5):2139-49. PubMed ID: 23419026
[TBL] [Abstract][Full Text] [Related]
8. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.
Giri AK; Apostol CR; Wang Y; Forte BL; Largent-Milnes TM; Davis P; Rankin D; Molnar G; Olson KM; Porreca F; Vanderah TW; Hruby VJ
J Med Chem; 2015 Nov; 58(21):8573-83. PubMed ID: 26465170
[TBL] [Abstract][Full Text] [Related]
10. Behavioral effects of benzylideneoxymorphone (BOM), a low efficacy µ opioid receptor agonist and a δ opioid receptor antagonist.
Mada S; Gerak LR; Soyer A; Maguire DR; Hu Z; Minervini V; Cunningham CW; France CP
Psychopharmacology (Berl); 2020 Dec; 237(12):3591-3602. PubMed ID: 32820390
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
Bender AM; Clark MJ; Agius MP; Traynor JR; Mosberg HI
Bioorg Med Chem Lett; 2014 Jan; 24(2):548-51. PubMed ID: 24365161
[TBL] [Abstract][Full Text] [Related]
12. Dual Pharmacophores Explored via Structure-Activity Relationship (SAR) Matrix: Insights into Potent, Bifunctional Opioid Ligand Design.
Nastase AF; Anand JP; Bender AM; Montgomery D; Griggs NW; Fernandez TJ; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2019 Apr; 62(8):4193-4203. PubMed ID: 30916966
[TBL] [Abstract][Full Text] [Related]
13. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.
Ananthan S
AAPS J; 2006 Mar; 8(1):E118-25. PubMed ID: 16584118
[TBL] [Abstract][Full Text] [Related]
14. Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.
Purington LC; Sobczyk-Kojiro K; Pogozheva ID; Traynor JR; Mosberg HI
ACS Chem Biol; 2011 Dec; 6(12):1375-81. PubMed ID: 21958158
[TBL] [Abstract][Full Text] [Related]
15. Bifunctional μ opioid and σ
Zhuang T; Xiong J; Hao S; Du W; Liu Z; Liu B; Zhang G; Chen Y
Eur J Med Chem; 2021 Nov; 223():113658. PubMed ID: 34175542
[TBL] [Abstract][Full Text] [Related]
16. The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment.
Pasquinucci L; Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Georgoussi Z; Fourla DD; Scoto GM; Ronsisvalle G
Life Sci; 2012 Jan; 90(1-2):66-70. PubMed ID: 22100511
[TBL] [Abstract][Full Text] [Related]
17. Heteromerization of the μ- and δ-opioid receptors produces ligand-biased antagonism and alters μ-receptor trafficking.
Milan-Lobo L; Whistler JL
J Pharmacol Exp Ther; 2011 Jun; 337(3):868-75. PubMed ID: 21422164
[TBL] [Abstract][Full Text] [Related]
18. Anti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonism.
Milan-Lobo L; Enquist J; van Rijn RM; Whistler JL
PLoS One; 2013; 8(3):e58362. PubMed ID: 23554887
[TBL] [Abstract][Full Text] [Related]
19. Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.
Bender AM; Griggs NW; Anand JP; Traynor JR; Jutkiewicz EM; Mosberg HI
ACS Chem Neurosci; 2015 Aug; 6(8):1428-35. PubMed ID: 25938166
[TBL] [Abstract][Full Text] [Related]
20. 7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands.
Fang X; Larson DL; Portoghese PS
J Med Chem; 1997 Sep; 40(19):3064-70. PubMed ID: 9301669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
